CN101909624A - 用咪唑并喹啉衍生物治疗结肠病或预防结肠直肠癌 - Google Patents

用咪唑并喹啉衍生物治疗结肠病或预防结肠直肠癌 Download PDF

Info

Publication number
CN101909624A
CN101909624A CN2008801223531A CN200880122353A CN101909624A CN 101909624 A CN101909624 A CN 101909624A CN 2008801223531 A CN2008801223531 A CN 2008801223531A CN 200880122353 A CN200880122353 A CN 200880122353A CN 101909624 A CN101909624 A CN 101909624A
Authority
CN
China
Prior art keywords
imidazoquinolie
treatment
derivant
imiquimod
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801223531A
Other languages
English (en)
Chinese (zh)
Inventor
J·毛斯
I·采兰伊
U·佩措尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meda AB
Original Assignee
Meda AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40419193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101909624(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Meda AB filed Critical Meda AB
Publication of CN101909624A publication Critical patent/CN101909624A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CN2008801223531A 2008-01-15 2008-12-23 用咪唑并喹啉衍生物治疗结肠病或预防结肠直肠癌 Pending CN101909624A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US645908P 2008-01-15 2008-01-15
US61/006,459 2008-01-15
PCT/EP2008/011088 WO2009089900A1 (en) 2008-01-15 2008-12-23 Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives

Publications (1)

Publication Number Publication Date
CN101909624A true CN101909624A (zh) 2010-12-08

Family

ID=40419193

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801223531A Pending CN101909624A (zh) 2008-01-15 2008-12-23 用咪唑并喹啉衍生物治疗结肠病或预防结肠直肠癌

Country Status (15)

Country Link
US (1) US8008319B2 (https=)
EP (1) EP2237780A1 (https=)
JP (1) JP2011509956A (https=)
CN (1) CN101909624A (https=)
AU (1) AU2008347400B2 (https=)
BR (1) BRPI0822002A2 (https=)
CA (1) CA2708559C (https=)
EA (1) EA018579B1 (https=)
GE (1) GEP20125605B (https=)
IL (1) IL205819A (https=)
MX (1) MX2010007699A (https=)
NZ (1) NZ586161A (https=)
UA (1) UA101339C2 (https=)
WO (1) WO2009089900A1 (https=)
ZA (1) ZA201003906B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962652B2 (en) 2009-10-22 2015-02-24 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
CN105899539B (zh) 2014-01-10 2021-11-09 博笛生物科技有限公司 用于免疫疗法的化合物和组合物
EP3166976B2 (en) 2014-07-09 2026-04-08 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
IL312120B2 (en) * 2017-06-23 2025-06-01 Birdie Biopharmaceuticals Inc Pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2078547C1 (ru) * 1995-11-28 1997-05-10 Центральный научно-исследовательский рентгено-радиологический институт МЗМП РФ Способ лечения полипоза желудка и двенадцатиперстной кишки
UA75622C2 (en) * 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
EP1351678A2 (en) * 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
US20060193789A1 (en) * 2002-10-25 2006-08-31 Foamix Ltd. Film forming foamable composition
DE602004014969D1 (de) * 2003-11-21 2008-08-21 Novartis Ag 1h-imidazochinolinderivate als proteinkinaseinhibitoren

Also Published As

Publication number Publication date
EP2237780A1 (en) 2010-10-13
JP2011509956A (ja) 2011-03-31
AU2008347400A1 (en) 2009-07-23
MX2010007699A (es) 2010-08-04
ZA201003906B (en) 2011-03-30
CA2708559C (en) 2015-10-06
EA018579B1 (ru) 2013-09-30
BRPI0822002A2 (pt) 2015-10-13
UA101339C2 (ru) 2013-03-25
US20090182005A1 (en) 2009-07-16
IL205819A (en) 2013-02-28
AU2008347400B2 (en) 2014-12-11
WO2009089900A1 (en) 2009-07-23
EA201001164A1 (ru) 2010-12-30
US8008319B2 (en) 2011-08-30
CA2708559A1 (en) 2009-07-23
NZ586161A (en) 2012-05-25
GEP20125605B (en) 2012-08-10
IL205819A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
CN101909624A (zh) 用咪唑并喹啉衍生物治疗结肠病或预防结肠直肠癌
Williams et al. Estrogen receptor beta as target for colorectal cancer prevention
Chen et al. Flavone inhibition of tumor growth via apoptosis in vitro and in vivo
Xia et al. Vorinostat upregulates MICA via the PI3K/Akt pathway to enhance the ability of natural killer cells to kill tumor cells
Spitler A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma.
Choi et al. Synergistic activity of paclitaxel, sorafenib, and radiation therapy in advanced renal cell carcinoma and breast cancer
Şenol et al. The role of inflammation in gastric cancer
Wang et al. Thalidomide suppresses breast cancer tumor growth by inhibiting tumor-associated macrophage accumulation in breast tumor-bearing mice
Wang et al. Licoricidin enhances gemcitabine-induced cytotoxicity in osteosarcoma cells by suppressing the Akt and NF-κB signal pathways
Ajideh et al. Potentiation of the therapeutic effect of intravesical BCG through synthetic and biogenic selenium nanoparticles in a nitrosamine-induced bladder cancer mouse model
CN102846594B (zh) 一种异戊烯基黄酮类化合物的药物用途
Choi et al. A case of erythroplasia of queyrat treated with imiquimod 5% cream and excision
Feng et al. Liriope muscari baily saponin C induces apoptosis and autophagy in HCT116 cells via ROS generation
Tseng et al. Magnolol’s Therapeutic Efficacy and Immunomodulatory Effects in Oral Squamous Cell Carcinoma
Gkoulioni et al. The efficacy of imiquimod on dysplastic lesions of the oral mucosa: an experimental model
KR102004363B1 (ko) 고미신 g 화합물을 유효성분으로 포함하는 유방암, 췌장암, 대장암 및 전립선암 치료용 조성물
HK1151220A (en) Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives
CN110538172B (zh) 铁死亡抑制剂在制备治疗金诺芬肝毒性的药物中的应用
Goharpour et al. Synergistic Effects of the Combination of Quercetin, Naringin, and Rutin on Cervical Cancer: Roles of Apoptosis and Autophagy
CN114569604A (zh) 一种下调衰老相关分泌表型的抗衰老组合药物及其应用
Mbodi et al. An overview of cervical cancer, chemotherapy as treatment and chemotherapy resistance
Sara et al. The effect of melatonin on apoptosis in hepatocellular carcinoma cell line: An experimental study
Aein et al. The effects of doxorubicin, ethanol extract and flavonoid-rich fraction of euphorbia splendida mobayen on the PARP level, and APC gene expression in HT-29 human colon cancer cell line
CN102935096B (zh) 过山蕨总黄酮在制备预防和治疗肿瘤药物方面的应用
JP2026507923A (ja) 腎細胞がん腫又はがんを治療するための方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1151220

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20101208

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1151220

Country of ref document: HK